# Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

> **NCT03003546** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Aggressive Non-Hodgkin Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Aggressive Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nab-paclitaxel/Rituximab-coated Nanoparticle AR160
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03003546
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-25
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03003546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03003546, "Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03003546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*